Evolution of the Average Target: Summit Therapeutics Inc.

Evolution of the Average Target - Summit Therapeutics Inc.

Evolution of the Target Price: Summit Therapeutics Inc.

Evolution of the Target Price - Summit Therapeutics Inc.

Changes in Analyst Recommendations: Summit Therapeutics Inc.

db25a5690fd66e6.joLQNtouo9l0p4woQFCBuH1s2P-rqF_Mwaz8XCYh-QI.weO0BbIc2o47095adx3Szz5c6pHz8WuNsevLaXBKkXv3wel-oFzzgUOXxQ~c91aebd13ce839ba3ceca55b4c14be5a
30/09 AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says MT
29/09 Stocks Defy the Pressure Zonebourse
10/09 Summit Therapeutics Shares Rise After Upgrade From Jefferies MT
09/09 Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 MT
25/08 Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines… Zonebourse
12/08 Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 MT
25/07 Jefferies Cuts Summit Therapeutics Price Target to $15 From $17, Hold Rating Kept MT
22/06 Analyst recommendations: Accenture, Conocophillips, Diamondback Energy, Oracle, Applied Materials… Zonebourse
28/05 BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says MT
23/05 Summit Therapeutics Shares Fall After HC Wainwright Downgrade MT
22/05 Bernstein Initiates Summit Therapeutics at Underperform MT
22/05 HC Wainwright Downgrades Summit Therapeutics to Neutral From Buy MT
04/05 U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower RE
18/12 Barclays Upgrades Summit Therapeutics to Equal Weight From Underweight, Adjusts Price Target to $18 From $16 MT
21/10/25 Analyst recommendations: Apple, Rivian, Goldman Sachs, Lyft, Morgan Stanley… Zonebourse
20/10/25 Summit Therapeutics Inc. Plans to Submit a BLA in Fourth Quarter 2025 for Ivonescimab Based on Harmoni Global Phase III Study Results CI
17/09/25 Barclays Initiates Summit Therapeutics at Underweight With $13 Price Target MT
04/09/25 Guggenheim Initiates Summit Therapeutics at Buy With $40 Price Target MT
19/08/25 Piper Sandler Initiates Summit Therapeutics at Neutral With $21 Price Target MT
14/08/25 Summit Therapeutics Pullback Seen as 'Overreaction' Amid Liquidity Options, Truist Says MT
01/07/25 UBS Initiates Summit Therapeutics at Buy With $30 Price Target MT
11/06/25 Leerink Partners Initiates Coverage on Summit Therapeutics With Underperform Rating, $12 Price Target MT
08/05/25 TD Cowen Initiates Summit Therapeutics at Buy MT
26/04/25 Top Midday Decliners MT
26/03/25 Citigroup Upgrades Summit Therapeutics to Buy From Neutral, Adjusts Price Target to $35 From $23 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+108.09%
+34.22%
+28.94%
+9.74%
+10.62%
+17.69%
+40.75%
+41.74%
+30.99%
+4.58%
Average +32.74%
Weighted average by Cap. +26.97%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
10.86GBP
Average target price
22.58GBP
Spread / Average Target
+107.85%
High Price Target
32.70GBP
Spread / Highest target
+201.06%
Low Price Target
8.896GBP
Spread / Lowest Target
-18.09%

Analyst Consensus Detail

Analyst consensus - Summit Therapeutics Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Summit Therapeutics Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - Summit Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. SMMT Stock
  4. Consensus Summit Therapeutics Inc.